CF PharmTech completes RMB 360 million in Series F financing, CEC Capital Group serves as exclusive financial advisor

Nearly RMB 1 billion in financing was completed across two rounds within 6 months, together resulting in one of the largest financings in the inhaler product market in China.

CF PharmTech (the “Company”) announced today that it has completed their Series F round of financing (RMB 360 million), which follows their Series E round of financing (RMB 630 million) in January 2020, resulting in a total of nearly RMB 1 billion raised. The investment in the Series F round was led by BioTrack Capital and China Capital Investment (CCI) Group Co., Ltd, with participation from other well-known institutions such as Hengxu Capital and SAIC Capital China, among others. Existing shareholders such as Passion Capital and YuanMing Capital also expanded their holdings.

CEC Capital Group served as the exclusive financial advisor for CF PharmTech in both their Series E and F rounds of financing.

CF PharmTech is a comprehensive pharmaceuticals company dedicated to providing high-quality respiratory medicines to patients around the world. Since its establishment, the Company has focused on the development of respiratory disease treatments and has established a complete R&D base for inhaled medications. The Company has also established production facilities for the global high-end market.

Respiratory diseases have become increasingly common worldwide. In China, the number of patients with asthma, COPD, and rhinitis is estimated to be in excess of 300 million, with the patient population growing rapidly. The "State Council Advisory on the Implementation of a Healthy China Initiative" issued by the State Council in July 2019 officially positioned China’s chronic obstructive pulmonary disease (COPD) at the same level as tumors, cardiovascular diseases, and diabetes, as one of the four major conditions affecting the health of its citizens.

Inhaled medications are a segment with extremely high barriers to entry, and are the gold standard drugs for the treatment of respiratory diseases. In order to enable the Chinese consumer to use products at a reasonable price and with reliable quality, CF PharmTech has assembled a team that has been actively engaged in the development of respiratory drug delivery technology with years of experience and expertise. Currently, the company is actively researching and developing new drugs,

About CEC Capital Group

Founded in 2000, CEC Capital Group is one of China’s leading investment banks focusing on the three major industries of healthcare, consumer, and TMT. The company is headquartered in Beijing, with offices in Shanghai. Its US affiliate, China eCapital Partners, LLC, has offices in Los Angeles and San Francisco.

In the three years from 2017 to 2019, CEC Capital Group has participated in financing and M&A transactions valued at a total of more than RMB 100 billion. In addition to its investment banking business, CEC Capital Group has been managing an RMB fund and a USD fund since 2014.

CEC Capital Group has the healthcare industry’s largest dedicated investment banking coverage team in China, with comprehensive coverage of the entire ecosystem and a market-leading position in the industry. The firm has advised on the largest number of healthcare-related private capital financing transactions over the past three years among China-based investment banks.